Eton Pharmaceuticals (ETON) said Friday that it acquired Galzin, an FDA-approved treatment for Wilson Disease.
The company plans to begin US commercialization in Q1 2025 and offer personalized support through its Eton Cares program, including a $0 co-pay for eligible patients.
Additionally, Eton said it acquired European rights to the product, which will continue to be marketed in Europe under the name Wilzin by a third-party distributor.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.